CONSORT flow diagram. Study schema. After 51 subjects were screened for the trial, a total of 34 subjects were enrolled and randomized in a 1:1 ratio. Subjects receiving pomalidomide in the LD (0.5 mg per day) cohort (n = 17) started and continued with the same daily dose. Subjects receiving pomalidomide in the HD (2 mg per day) cohort (n = 17) started with the 0.5 mg per day dose with 0.5-mg increment increases every 2 weeks until reaching the 2 mg per day dose. The 6-month ORR was the primary endpoint of the study.